EUVIMEDEUVIMED entdecken
Crossref

Characteristics and Impact of p16 Expression in Patients With Oropharyngeal Squamous Cell Carcinoma in Tanzania

Godwin Nnko iD, Saloni Patel iD, Eulade Rugengamanzi iD, Shafii S Ramadhani iD, Dammy A Shimbo, Mathias Banzi iD, Godfrey Malangwa iD, Getruda Mashashi, Glory Makupa iD, Milpah Moturi, Leila Mwakipunda iD, Jesse Jonathan iD und 9 weitere

JCO Global Oncology · 2025

DOI: 10.1200/go-24-00652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Godwin Nnko und 20 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Care Center, Kilimanjaro Christian Medical Centre, Moshi, Tanzania. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Cyclin-Dependent Kinase Inhibitor p16, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Oropharyngeal cancer is on the rise, despite declines in other head and neck cancers. The primary cause of this increase is human papillomavirus (HPV) infection, which accounts for over a quarter of new cancer patients in Tanzania. These cancers are largely preventable through HPV vaccination. HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is recognized as a distinct molecular and clinical entity, with unique demographics, staging, survival, and prognosis. International guidelines recommend that all staging, prognosis, and treatment decisions for OPSCC occur after determining the p16 expression, a surrogate immunohistochemical marker for HPV infection. However, current Tanzanian guidelines and clinical practice do not incorporate p16 immunohistochemistry (IHC) testing, despite the availability of qualified pathologists and laboratories. PATIENTS AND METHODS This retrospective hospital-based cohort study was conducted at the Ocean Road Cancer Institute (ORCI) and Muhimbili National Hospital in Dar es Salaam, Tanzania. A total of 83 patients with OPSCC were included. We assessed the sociodemographic and clinicopathologic profiles and the impact of p16 expression on overall survival (OS) in patients with OPSCC treated at the ORCI. RESULTS The prevalence of p16-positive OPSCC was found to be 43.4%. Patients with p16-positive tumors were younger and predominantly male and had a 3-year OS of 36% compared with 16.6% in those with p16-negative tumors. CONCLUSION Our findings support the use of p16 IHC as a prognostic biomarker for OPSCC. In addition, the high prevalence of p16-positive OPSCC in our cohort suggests the broader implementation of gender-neutral HPV vaccination across Tanzania.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oropharyngeal NeoplasmsCyclin-Dependent Kinase Inhibitor p16Squamous Cell Carcinoma of Head and NeckCarcinoma, Squamous CellHumansMaleFemaleTanzaniaMiddle AgedRetrospective StudiesAgedAdultPapillomavirus InfectionsPrognosisBiomarkers, Tumor

Substanzen

Cyclin-Dependent Kinase Inhibitor p16CDKN2A protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Cancer Care Center, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
  • Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.
  • Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
  • Johns Hopkins University School of Medicine, Baltimore, MD.
  • Department of Oncology, the Butaro Cancer Center of Excellence, Butaro, Rwanda.
  • Clinical Division, Medical School, University of Global Health Equity (UGHE), Butaro, Tanzania.

ORCID-Profile: Godwin Nnko, Saloni Patel, Eulade Rugengamanzi, Shafii S Ramadhani, Mathias Banzi, Godfrey Malangwa, Glory Makupa, Leila Mwakipunda, Jesse Jonathan, Cepheline Idrissa, Nur Antar Mabruk, Harrison Chuwa, Alexis A Miller, Jerry Ndumbalo

Zitieren

APA

Nnko, G., Patel, S., Rugengamanzi, E., Ramadhani, S. S., Shimbo, D. A., Banzi, M., Malangwa, G., Mashashi, G., Makupa, G., Moturi, M., Mwakipunda, L., Jonathan, J., Ramadhani, A., Gisiri, M., Idrissa, C., Mabruk, N. A., Karia, A., Sifueli, I., Chuwa, H., …, & Ndumbalo, J. (2025). Characteristics and Impact of p16 Expression in Patients With Oropharyngeal Squamous Cell Carcinoma in Tanzania. JCO Global Oncology. https://doi.org/10.1200/go-24-00652

Vancouver

Nnko G, Patel S, Rugengamanzi E, Ramadhani SS, Shimbo DA, Banzi M, et al. Characteristics and Impact of p16 Expression in Patients With Oropharyngeal Squamous Cell Carcinoma in Tanzania. JCO Global Oncology. 2025. doi:10.1200/go-24-00652

BibTeX
@article{Nnko2025,
  author = {Nnko, Godwin and Patel, Saloni and Rugengamanzi, Eulade and Ramadhani, Shafii S and Shimbo, Dammy A and Banzi, Mathias and Malangwa, Godfrey and Mashashi, Getruda and Makupa, Glory and Moturi, Milpah and Mwakipunda, Leila and Jonathan, Jesse and Ramadhani, Aisha and Gisiri, Mwitasrobert and Idrissa, Cepheline and Mabruk, Nur Antar and Karia, Angela and Sifueli, Innocent and Chuwa, Harrison and Miller, Alexis A and Ndumbalo, Jerry},
  title = {Characteristics and Impact of p16 Expression in Patients With Oropharyngeal Squamous Cell Carcinoma in Tanzania},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-24-00652}
}
Kostenlos starten →